A NEW WAY FOR A NEW WORLD STARTS
TODAY
Evolution
- Scaling the Value Chain
- Our Innovation Journey
2024
Becomes the first to launch biosimilar of popular anti-diabetic drug, Liraglutide, in India.
for KN035 (Envafolimab) for multiple geographies around the world. Envafolimab is innovative immuno-oncology product and
the first recombinant humanized single domain antibody against PD-L1 in a Sub-Q formulation.
2023
the Science Based Target initiative.
in GLS to Nirma Limited.
Announces signing of distribution and license agreements with Cosmo Pharmaceuticals for Winlevi® in Europe and South Africa.
2022
U.S. FDA grants approval for RYALTRIS®, the company’s first global branded specialty drug for the treatment of symptoms of seasonal allergic rhinitis in adults and paediatric patients 12 years of age and older. Marketed by Hikma in the U.S. and Bausch Health in Canada.
Becomes the first Indian pharmaceutical company to raise a Sustainability-Linked Loan.
Continues to expand its over-the-counter portfolio in the USA with the acquisition of Approved Abbreviated New Drug Application (ANDA) from Wockhardt Limited.
2021
Glenmark Life Science gets listed on the Indian bourses, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
2020
2019
Spins out its Active Pharmaceutical Ingredients (API) arm, Glenmark Life Sciences.
2018
Glenmark’s top respiratory pipeline candidate, for review as treatment for seasonal allergic rhinitis.
2016
Launches differentiated generics: introduces Ezetimibe, generic version of Zetia® in the USA.
2015
receives approval for its generic version in Russia.
2014
Commissions new manufacturing facility for injectables and oral solids in Monroe, North Carolina, USA.
2009
Commisions third research and development (R&D) centre in Taloja, Maharashtra, India.
2007
The manufacturing facility is now known as the Vysoke Myto.
2006
Makes debut in the Oncology segment with the launch of Aprecap® (aprepitant capsules) in India.
2005
Launches front-end commercial sales along with its first generic product in the USA.
Sets up its first manufacturing facility built to U.S. FDA specifications in Goa, India.
2004
Enters the European market by incorporating its subsidiary, Glenmark Pharmaceuticals Europe Limited.
2003
Establishes North American subsidiary, Glenmark Pharmaceuticals, Inc.
2002
Acquires API manufacturing units at Ankleshwar, Gujarat.
2001
Commences the production of APIs at Kurkumbh manufacturing facility in Maharashtra.
2000
Goes public; commands a market capitalization of USD 40 million on the Indian bourses, BSE and NSE.
1999
Sets up its first Research and Development center at Sinnar.
1987
Enters the Respiratory segment with the launch of Ascoril®, a cough expectorant, which has emerged as one of its most successful brands.
1983
Commissions its first manufacturing unit in Nashik.
1980
Commences operations in Russia and CIS.
1979
Makes its foray into the Dermatology therapy area with the launch of ‘Candid® Cream’; a top selling brand even today.
1977
Mr. Gracias Saldanha (Founder Emeritus) lays the foundation stone of Glenmark Pharmaceuticals.
2024
Glenmark and Ichnos take a collaborative leap to accelerate innovation in cancer treatment with the formation of their alliance, ‘Ichnos Glenmark Innovation’ (IGI). This alliance combines Glenmark’s research and development proficiencies in small molecules with those of Ichnos in novel biologics to continue developing cutting-edge therapy solutions that treat hematological malignancies and solid tumors. IGI’s pipeline features three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia and solid tumors, which are currently undergoing clinical trials.
2023
Glenmark Specialty, S.A. (GSSA) receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatment of patients with advanced solid tumors and lymphomas.
ISB 880, the out-licensed immunology asset of Ichnos, progresses to Phase 1 studies (initiated by its partner, Almirall, S.A.)
Ichnos receives Orphan Drug Designation from the U.S. FDA for two of its assets – ISB 1442, a first-in-class biparatopic 2+1 BEAT® bispecific antibody, and ISB 2001, a first-in-class Trispecific Antibody.
Ichnos makes an oral presentation at the 64th ASH Annual Meeting for ISB 2001, its first TREAT™ trispecific (BCMAxCD38xCD3) antibody.
Ichnos enters into an out-licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics.
2022
clinical trial of GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor.
2021
Ichnos out-licenses its IL-1RAP antagonist, ISB 880, to Almirall, S.A. for an upfront milestone payment of EUR 20.8 million.
as the first-in-class CD38 x CD47 2+1 Biparatopic BEAT® bispecific antibody for the treatment of relapsed/refractory multiple myeloma. ASH is the world’s premier event in malignant and non-malignant hematology; becomes the first India-origin company to be invited to make an oral presentation at ASH.
2019
Spins out an innovation subsidiary, Ichnos Sciences Inc. (Ichnos), to focus on immuno-oncology.
2018
Signs an exclusive licensing agreement with Harbour Biomed in Greater China to develop, manufacture and commercialize GBR 1302.
2016
Adds GBR 1302, GBR 1342 and GBR 1372 from the BEAT® platform to expand its Oncology portfolio.
2014
Establishes new antibody manufacturing facility to provide clinical GMP-grade biologics for clinical trials in La Chaux-de-Fonds, Switzerland.
2012
Out-licenses mPEGS-1 Inhibitor to Forest Laboratories for USD 15 million (upfront payment).
2011
Out-licenses its first New Biological Entity, GBR 500, to Sanofi-Aventis for USD 55 million (upfront and milestone payments).
2010
Out-licenses GRC 15300, its first-in-class TRPV3 antagonist, to Sanofi-Aventis for USD 25 million (upfront payment).
2007
Out-licenses first portfolio, TRPV1 antagonist molecules, to Eli Lilly for USD 45 million.
2006
Establishes its first research and development (R&D) Centre for New Biological Entities (NBE) / Biologics research in Switzerland.
Out-licenses its third molecule, Melogliptin, to Merck KGaA for USD 31 million (total payment).
2005
Strikes its second out-licensing deal for Oglemilast (GRC 3886) with Teijin Pharma, Japan for USD 6 million (upfront payment).
2004
(upfront and milestone payments).
2000
Second R&D center set up at Mahape, Navi Mumbai, to drive innovation in Novel Chemical Entities / Small Molecules.